X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Achillion Pharmaceuticals Biotech Facility

Yuvraj_pawp by Yuvraj_pawp
8th August 2014
in Americas, Projects

Achillion Pharmaceuticals, Inc., which was founded in February 2000 as one of the largest biotech start-ups in the USA, occupies a renovated space in the George Street Technology Center in downtown New Haven, Connecticut, across from Yale Medical School. The new facility is dedicated to developing biotechnology products on a commercial basis. The facility is rented out to a number of other companies in the biotechnology sector, besides Achillon (thus functioning as an incubator). Achillion has assembled the necessary scientific, technological and human resources to discover and develop new products addressing serious unmet medical needs. Achillion is a privately held company financed by Schroder Ventures, Atlas Venture, Advent International and Connecticut Innovations.

BIOTECHNOLOGY FACILITY ACTIVITIES

 

Achillion, in partnership with Yale University, is a product-focused pharmaceutical company dedicated to the discovery and commercial development of innovative therapeutic agents, with a particular emphasis on antiviral drugs to treat diseases caused by hepatitis B and C viruses (HCV and HBV), herpes viruses, and the human immunodeficiency virus (HIV).

The company, which originally planned to locate in New Jersey, moved to Connecticut so it could enter into a partnership with Yale University and Yale researchers. The company is now pursuing development of lead drug candidates, building its internal discovery teams and structuring a variety of business and research collaborations.

THERAPEUTIC AGENTS PRODUCTION

 

The company’s proprietary lead drug candidate (ACH126443) is under rapid advancement for the treatment of HIV and HBV infections. Achillion’s drug discovery and optimisation engine embodies both a conventional medicinal chemistry approach directed at classical molecular targets and the core breakthrough Zinc Finger Targeting Technology (ZFTT) for drug discovery.

TECHNOLOGY CENTRE AT NEW HAVEN

 

Achillion Pharmaceuticals and Molecular Staging became the first tenants in the new biotech facility located at 300 George St. The owner of the property, Winstanley Associates, spent a substantial amount of money to make what was once an SNET (phone company) building attractive to biotech tenants.

Winstanley Associates acquired the 550,000ft² building in downtown New Haven. A block from the medical school, this building houses Achillion and three other companies. The nine-storey facility was already outfitted with fibre-optic communication systems.

Winstanley planned a combination of laboratory space for biotech start-ups and offices for information technology and telecommunications start-ups.

THE WINSTANLEY PROJECT

 

The Winstanley project represents a multilateral commitment to biotechnology in New Haven. The predecessor of 300 George St., Science Park was launched in the 1980s with the help of Yale funds but faced debt and vacancy for many years. Now, however, the complex is a vigorous incubator for biotech start-ups and recently expanded to include 500,000ft of new space.

Several of the building’s aspects are ideal for biotech firms. For example, large chaseways used in its now obsolete heating system was easily converted to an exhaust system vital for biotechnology research. Installing a similar system in another building could be prohibitively expensive.

BIOTECHNOLOGY AND NEW ENGLAND

 

The success of biotechnology companies has made them increasingly valuable to communities and developers, as demonstrated by the recent sale of the former Southern New England Telephone property to Winstanley Enterprises for more than $27 million.

Despite projects like 300 George Street, biotechnology has yet to generate many jobs in the area, but the industry plays an important role in revitalising the local economy. The conversion of the downtown site in close proximity to Yale University’s School of Medicine is supported by a private investment of close to $50 million by the developer, Winstanley Enterprises.

The City and State have funded the construction of an adjacent parking garage, as well as supported nearby restaurants, theatres, a park and the Omni hotel, creating a desirable and attractive downtown location next to Yale’s Medical School.

Tags: America
Previous Post

Juno Closes $134M Series B Round

Next Post

GSK’s New Biopharmaceutical Plant

Related Posts

Cellbox Solutions Establishes Subsidiary in the USA
Americas

Cellbox Solutions Establishes Subsidiary in the USA

24th September 2021
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
Americas

US Allows Johnson & Johnson Covid Vaccination To Resume

26th April 2021
POINT Biopharma to Launch First US Manufacturing Facility in Indiana
Americas

POINT Biopharma to Launch First US Manufacturing Facility in Indiana

5th June 2020
AMRI Increases Hydroxychloroquine Sulfate API Production in U.S. to Meet Potential COVID-19 Demand
Americas

AMRI Increases Hydroxychloroquine Sulfate API Production in U.S. to Meet Potential COVID-19 Demand

5th May 2020
Elsevier and FDA to work on AI algorithm for drug-induced liver injury
Americas

Elsevier and FDA to work on AI algorithm for drug-induced liver injury

26th November 2019
Lilly to invest $400m to boost manufacturing capacity in US
Americas

Lilly to invest $400m to boost manufacturing capacity in US

26th November 2019
Next Post

GSK’s New Biopharmaceutical Plant

Latest News

NIH begins study of allergic reactions to Covid-19 vaccines
News

To Treat COVID WHO Approves Monoclonal Antibody Tocilizumab

18th February 2022
Envirotainer introduces the RAP for the future - part of the Releye series
Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

14th February 2022
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

14th February 2022
Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease
Press Statements

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

14th February 2022
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In